The U.S. Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent ...
NDAQ:HUMA) Humacyte Provides Update on Commercial Launch and Pricing of Symvess(TM) (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma ...
Plans for filing an IND was agreed with the FDA in a recent meeting – – Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association’s Scientific ...
Symvess is a sterile, acellular tissue-engineered vessel composed of extracellular matrix proteins usually found in human blood vessels and is manufactured using human vascular smooth muscle cells ...
Department of Orthopedics, Peking University Third Hospital, No. 49 North Garden Road, Haidian, 100191 Beijing, China Engineering Research Center of Bone and Joint Precision Medicine, Peking ...
The U.S. Food and Drug Administration (FDA) has officially approved Symvess, the first acellular tissue-engineered vessel designed to repair damaged arteries in extremities. This innovative ...
A new type of bioengineered blood vessel has shown strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...
22, 2025 — Pathogen-fighting immune cells called tissue-resident memory CD8 T cells (TRM cells) go through a surprising transformation -- and relocation -- as they fight infections in the small ...
Jan. 15, 2025 — While most known types of DNA damage are fixed by our cells' in-house DNA repair mechanisms, some forms of DNA damage evade repair and can persist for many years, new research shows.
Development and Trends in Medical Aesthetic Material Technology Recent advancements in biocompatible materials have significantly improved the safety and effectiveness of medical aesthetic treatments ...